Skip to main content

Tuberculous meningitis.

Publication ,  Journal Article
Wilkinson, RJ; Rohlwink, U; Misra, UK; van Crevel, R; Mai, NTH; Dooley, KE; Caws, M; Figaji, A; Savic, R; Solomons, R; Thwaites, GE ...
Published in: Nat Rev Neurol
October 2017

Tuberculosis remains a global health problem, with an estimated 10.4 million cases and 1.8 million deaths resulting from the disease in 2015. The most lethal and disabling form of tuberculosis is tuberculous meningitis (TBM), for which more than 100,000 new cases are estimated to occur per year. In patients who are co-infected with HIV-1, TBM has a mortality approaching 50%. Study of TBM pathogenesis is hampered by a lack of experimental models that recapitulate all the features of the human disease. Diagnosis of TBM is often delayed by the insensitive and lengthy culture technique required for disease confirmation. Antibiotic regimens for TBM are based on those used to treat pulmonary tuberculosis, which probably results in suboptimal drug levels in the cerebrospinal fluid, owing to poor blood-brain barrier penetrance. The role of adjunctive anti-inflammatory, host-directed therapies - including corticosteroids, aspirin and thalidomide - has not been extensively explored. To address this deficit, two expert meetings were held in 2009 and 2015 to share findings and define research priorities. This Review summarizes historical and current research into TBM and identifies important gaps in our knowledge. We will discuss advances in the understanding of inflammation in TBM and its potential modulation; vascular and hypoxia-mediated tissue injury; the role of intensified antibiotic treatment; and the importance of rapid and accurate diagnostics and supportive care in TBM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

October 2017

Volume

13

Issue

10

Start / End Page

581 / 598

Location

England

Related Subject Headings

  • Tuberculosis, Meningeal
  • Neurology & Neurosurgery
  • Humans
  • Anti-Infective Agents
  • Animals
  • Adrenal Cortex Hormones
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1113 Opthalmology and Optometry
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wilkinson, R. J., Rohlwink, U., Misra, U. K., van Crevel, R., Mai, N. T. H., Dooley, K. E., … Tuberculous Meningitis International Research Consortium, . (2017). Tuberculous meningitis. Nat Rev Neurol, 13(10), 581–598. https://doi.org/10.1038/nrneurol.2017.120
Wilkinson, Robert J., Ursula Rohlwink, Usha Kant Misra, Reinout van Crevel, Nguyen Thi Hoang Mai, Kelly E. Dooley, Maxine Caws, et al. “Tuberculous meningitis.Nat Rev Neurol 13, no. 10 (October 2017): 581–98. https://doi.org/10.1038/nrneurol.2017.120.
Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al. Tuberculous meningitis. Nat Rev Neurol. 2017 Oct;13(10):581–98.
Wilkinson, Robert J., et al. “Tuberculous meningitis.Nat Rev Neurol, vol. 13, no. 10, Oct. 2017, pp. 581–98. Pubmed, doi:10.1038/nrneurol.2017.120.
Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE, Tuberculous Meningitis International Research Consortium. Tuberculous meningitis. Nat Rev Neurol. 2017 Oct;13(10):581–598.

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

October 2017

Volume

13

Issue

10

Start / End Page

581 / 598

Location

England

Related Subject Headings

  • Tuberculosis, Meningeal
  • Neurology & Neurosurgery
  • Humans
  • Anti-Infective Agents
  • Animals
  • Adrenal Cortex Hormones
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1113 Opthalmology and Optometry
  • 1109 Neurosciences